The Fort Worth Press - Radius Pharmaceuticals Expands Abaloparatide Licensing Agreement with Theramex Granting Additional Commercialization Rights Including Mexico, Canada, South Africa, Israel, and Russia

USD -
AED 3.672495
AFN 64.000314
ALL 82.253977
AMD 360.509431
ANG 1.790403
AOA 917.499428
ARS 1552.284702
AUD 1.48346
AWG 1.8025
AZN 1.697632
BAM 1.779545
BBD 2.01413
BDT 124.905034
BGN 1.77347
BHD 0.377331
BIF 3007.507166
BMD 1
BND 1.288858
BOB 11.66537
BRL 5.778804
BSD 1.000059
BTN 93.425596
BWP 13.998644
BYN 3.001178
BYR 19600
BZD 2.011401
CAD 1.42811
CDF 2317.999791
CHF 0.838815
CLF 0.025259
CLP 994.110012
CNY 6.66455
CNH 6.665535
COP 3315.05
CRC 445.481718
CUC 1
CUP 24.000873
CVE 100.328012
CZK 22.107101
DJF 177.720338
DKK 6.781775
DOP 60.559465
DZD 136.951012
EGP 53.7264
ERN 15
ETB 164.140883
EUR 0.90739
FJD 2.296803
FKP 0.758367
GBP 0.756145
GEL 2.594965
GGP 0.758367
GHS 11.73543
GIP 0.758367
GMD 73.501804
GNF 8860.460038
GTQ 7.643069
GYD 209.144677
HKD 7.846205
HNL 26.886001
HRK 6.831965
HTG 131.024035
HUF 332.705959
IDR 18268.2
ILS 3.254645
IMP 0.758367
INR 93.45945
IQD 1516.079284
IRR 1925253.999815
ISK 124.130485
JEP 0.758367
JMD 158.919789
JOD 0.709003
JPY 159.245985
KES 129.999866
KGS 87.448984
KHR 4080.072793
KMF 447.497229
KPW 900.00035
KRW 1334.25967
KWD 0.31158
KYD 0.833458
KZT 444.016797
LAK 22523.690592
LBP 89554.848894
LKR 332.782835
LRD 168.006442
LSL 16.919297
LTL 2.95274
LVL 0.60489
LYD 6.462884
MAD 9.981438
MDL 18.311519
MGA 4549.44565
MKD 55.861384
MMK 2099.8229
MNT 3605.49036
MOP 8.082545
MRU 40.524838
MUR 47.860197
MVR 15.410202
MWK 1734.212921
MXN 18.413075
MYR 4.093596
MZN 63.910227
NAD 16.918528
NGN 1348.670466
NIO 36.80602
NOK 9.59563
NPR 149.481136
NZD 1.81649
OMR 0.384501
PAB 1.000032
PEN 3.415635
PGK 4.499381
PHP 63.585016
PKR 276.505202
PLN 3.993785
PYG 6230.864068
QAR 3.64562
RON 4.852297
RSD 106.739941
RUB 82.05711
RWF 1480.116648
SAR 3.756442
SBD 8.098361
SCR 13.825232
SDG 601.499925
SEK 10.096805
SGD 1.287735
SHP 0.758581
SLE 23.049694
SLL 20969.503664
SOS 571.501363
SRD 37.437951
STD 20697.981008
STN 22.292284
SVC 8.750364
SYP 13002.000337
SZL 16.918877
THB 33.77702
TJS 9.216015
TMT 3.51
TND 3.026264
TOP 2.40776
TRY 50.414697
TTD 6.771395
TWD 32.925901
TZS 2650.002957
UAH 45.33545
UGX 4149.985442
UYU 40.627659
UZS 12019.053598
VES 914.603599
VND 25712.5
VUV 120.845902
WST 2.802705
XAF 595.208663
XAG 0.021073
XAU 0.000259007303
XCD 2.70255
XCG 1.802383
XDR 0.707052
XOF 595.208663
XPF 108.509428
YER 236.503646
ZAR 16.92348
ZMK 9001.222553
ZMW 20.486504
ZWL 321.999592
SSP 5946.953244
MXV 2.06566
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Radius Pharmaceuticals Expands Abaloparatide Licensing Agreement with Theramex Granting Additional Commercialization Rights Including Mexico, Canada, South Africa, Israel, and Russia
Radius Pharmaceuticals Expands Abaloparatide Licensing Agreement with Theramex Granting Additional Commercialization Rights Including Mexico, Canada, South Africa, Israel, and Russia

Radius Pharmaceuticals Expands Abaloparatide Licensing Agreement with Theramex Granting Additional Commercialization Rights Including Mexico, Canada, South Africa, Israel, and Russia

Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. ("Radius" or the "Company"), a specialty biopharmaceutical company focused on bone health and related areas, announced today it has granted Theramex the exclusive commercialization rights to ELADYNOS® (abaloparatide), a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women and men at increased risk of fractures, for Mexico, Canada, Israel, South Africa, and Russia. Theramex will also have the opportunity to commercialize ELADYNOS® in other agreed upon unpartnered regions. Abaloparatide is marketed in the U.S. by Radius under the tradename TYMLOS®.

Text size:

Under the License Agreement, Radius will receive an upfront and milestone payment plus tiered royalties.

"Theramex has been an excellent collaborative partner, and we are very pleased to expand our abaloparatide partnership to include additional important global markets," said Scott Briggs, Chief Executive Officer of Radius. "Radius is committed to making abaloparatide accessible to patients, and the expansion of our existing partnership helps provide access to additional patients in need of osteoporosis treatment options."

"Following the launch of abaloparatide in Europe, we are excited to bring this innovative product to more patients globally and drive further growth through our direct markets and our commercial partnerships. This agreement expands our successful relationship with Radius, and we look forward to continuing our close collaboration," said Rob Stewart, Chief Executive Officer of Theramex.

In addition to these new territories, Theramex will continue to commercialize and distribute ELADYNOS® on an exclusive basis in the European Economic Area, the United Kingdom, Australia, and Brazil. ELADYNOS® received approval in the European Economic Area in December 2022 and Australia in November 2024 and has been launched in select countries.

About Radius:

Radius is a global biopharmaceutical company dedicated to transforming the future for underserved, global patient populations in bone health and related areas. Radius' lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture, and in December 2022 to increase bone density in men with osteoporosis at high risk for fracture. Radius also has an exclusive licensing and distribution agreement for the U.S. rights to BINOSTO® (alendronate sodium) effervescent tablet for oral solution, expanding the Company's presence in bone health.

About Theramex:

Theramex is a leading global specialty pharmaceutical company dedicated to women and their health. Theramex supports women at different stages of their lives by providing a broad portfolio of innovative and established brands covering osteoporosis, contraception, fertility, menopause and uterine health. Theramex's commitment is to listen to and understand its patients, serve their needs and offer healthcare solutions to help improve their lives. Theramex's vision is to be a lifetime partner for women and the healthcare professionals who treat them by providing patient-focused and effective solutions that care for and support women through different stages of their life.

Contacts:
Al Medwar: Senior Vice President, Business and Corporate Development, Radius
Email: [email protected]

Edward Rees: Chief Corporate Development Officer, Theramex
Email: to [email protected]

SOURCE: Radius Health

W.Matthews--TFWP